Evonile Pharma Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-b50b64e724cd580cb426a508.pdf

Key Takeaways


The Commercial Reset

Vikas Gupta: “It's almost like -- there are two cases, and many a times we internally talk about it. And there's a painting and you have to -- and there is a blank canvas. Sometimes you're just writing on the blank canvas. In this case, you have to erase that painting, make the canvas blank and then again get going about painting it.”

Cost Build-Up & Margin Trajectory

Vikas Gupta: “So in the short term to medium term you will see a dip because these costs will be built upfront and then revenue starts happening over a period of time. But I think from here on, next financial year, we would be better than this. It will take us to come back to this level maybe by two to three years, we should be coming back to upwards of 20%.”

Minipress XL Acquisition & Capital Deployment

Bhagwat Singh Deora: “If today I'm going to get an EBITDA -- starting EBITDA of INR90-odd crores coming in from a Minipress brand, which can grow significantly for my investment of INR1,250 crores, that itself should answer your question into what is the return.”

Therapy Area Platforms & Portfolio Build-Out


M&A Strategy & Discipline

Vikas Gupta: “If there is a very attractive proposition, but it's coming at a price that we know we can't create value from there, I would just pass.”

Market Context & Legacy Brand Strength


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue aspirationAt least double the current base, organicNext four to five years
Distribution reach4,000–5,000 distributors for pan-India coverageWithin next 1–1.5 months
Sales force operationalTeam fully on-board and operationalEnd of Q3 FY27 (around December)
Incremental cost run rateINR40–50 crores per quarter addedStarting Q2; full run rate from Q4
Margin recoveryReturn to upwards of 20% marginsTwo to three years
Minipress debt repaymentSignificant portion of acquisition debt repaidBefore end of current financial year
Debt funding clarityBoard approval to explore capital-raising optionsClarity expected in a month
Dr. Reddy’s termination impactFinancial impact quantifiedAfter Q2
Name changeShareholder approval sought for parent entity name changeUndated

Key Metrics

MetricQ1 FY27
Revenue (annualized run rate)INR650-odd crores (per an analyst's math)
Last year operating margin27%
Margin recovery targetupwards of 20%, expected in 2 to 3 years
Incremental quarterly cost run rateINR40 crore to INR50 crores, starting from next quarter
Historical quarterly cost run rateINR10 crores to INR15 crores
Revenue doubling aspirationdoubling in the next 4 to 5 years from the FY27 annualized base
Indian pharma market growtharound 9% to 10%
Minipress XL reported revenue (IQVIA, Mar/Jul '26)INR228 crores
Minipress XL market share55% to 60%
Minipress XL CAGR (last few years)6.5%
Minipress XL acquisition investmentINR1,250 crores, with starting EBITDA of INR90-odd crores
Ophthalmology portfolio size (Pagenax + Accentrix)close to almost INR100 crores plus
Ophthalmology in-licensing upfront feeINR10 crores
Healthcare practitioners to be coveredalmost 150,000
Distributor network targetmore than 4,000 to 5,000 distributors
ChrysCapital stake70.68%
Open-offer priceINR860
M&A discounting ratearound 12, 12.5%
Payback period target for acquisitions (post-synergies)8 to 9 years
Income tax liabilityabout INR300 odd crores, provided in books